{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"311"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"329"}],"units":"Participants"}],"description":"An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. The final analysis for participants who experienced an AE was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who experienced an AE is reported here for all randomized participants who received ≥1 dose of study treatment.","groups":[{"description":"Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG000","title":"Vorinostat"},{"description":"Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants randomized to a study arm who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)","title":"Number of Participants Who Experienced an AE","type":"PRIMARY","unitOfMeasure":"Participants"}